Page 52 - Solid Tumors News Today

Ripretinib failed to prolong PFS compared with sunitinib among patients with gastrointestinal stromal tumor who received prior treatment with imatinib, according to results of the phase 3 INTRIGUE study released by the agent’s manufacturer.Ripretinib (Qinlock, Deciphera Pharmaceuticals), a switch-control tyrosine kinase inhibitor, uses a dual mechanism of action that regulates the kinase

/PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...

Stereotactic body radiotherapy (SBRT) significantly improved progression- free survival for patients with oligoprogressive, metastatic lung cancer but not breast cancer.

Investegate announcements from Cybrexa Therapeutics, Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the...

Stereotactic body radiation therapy (SBRT) significantly improved progression-free survival in oligoprogressive, metastatic lung cancer, but not breast cancer.

/PRNewswire/ -- DelveInsights Bone Metastasis in Solid Tumors Market Insights report proffers a detailed comprehension of Bone Metastasis in Solid Tumors...

SACITUZUMAB  GOVITECAN  RECEIVES  POSITIVE  CHMP  OPINION  AS  2L  TREATMENT  FOR  ADULT  PATIENTS  WITH  METASTATIC  TRIPLE-NEGATIVE  BREAST  CANCER -- Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Go...

-- Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Govitecan Significantly Improved Overall Survival in 2L vs. Physician's Choice of Chemotherapy in Metastatic Triple-Negative

Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer